Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion to recommend the variation to the terms of the marketing authorization for Otsuka Pharmaceutical's Abilify.
Subscribe to our email newsletter
Abilify is intended for the treatment of schizophrenia. It is also indicated for the treatment of moderate to severe manic episodes in bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.